Aethlon Medical, Inc. Aethlon Medical (OTCBB:AEMD) creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression.
Symbol: OTCBB: AEMD
Sector: Biotech / Pharma
Website: aethlonmedical.com
SEC Filings: details
Request News & Updates from Investorideas.com Showcase Stock AEMD
AddThis Social Bookmark Button Research Report by Redchip.com
OTCBB:AEMD slide show / media A Novel Therapeutic Strategy to Address Cancer Click here
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats. The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Products
Hemopurifier®
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 min.
Highlights of the Hemopurifier®
Multi-patented first-in-class medical device to selectively capture viruses and immunosuppressive toxins from the entire circulatory system Preserves immune cells needed to combat cancer and viral infections Inhibits viral replication by clearing viruses prior to cell and organ infection Provides expansive treatment pipeline into both cancer and infectious disease Establishes first therapeutic strategy to address the immunosuppression caused by cancer Safety of the device has been demonstrated in human studies Significant reduction of viral load demonstrated in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients Demonstrated improved immune function of HIV patient clinically defined with AIDS Near-term commercialization strategy established in India Investigational device exemption (IDE) on file with FDA GMP manufacturing has been established Positioned as an adjunct to accelerate the benefit of HCV drug regimens Provides candidate treatment solution for drug resistant HIV/AIDS patients Leading broad-spectrum countermeasure against bioterror and pandemic threats Treatment mechanism is being leveraged to create high-sensitivity diagnostic and biomarker discovery productsutes.
Executive Team
James A. Joyce
Chairman and Chief Executive Officer
James A. Joyce founded Aethlon Medical in May 1998, and presently serves as Chairman, President and Chief Executive Officer. During Mr. Joyce's tenure, Aethlon has evolved the concept of a medical device to treat infectious disease into a reality of treating infected patients in a clinical trial environment. The resulting Hemopurifier® technology is positioned to treat global pandemic issues such as HIV/AIDS, Hepatitis-C, and pathogens most likely to be weaponized for use in bioterrorism. Mr. Joyce has been an active participant in the emerging biodefense industry. He has testified before Congress on issues related to Project BioShield legislation and the deployment of the Hemopurifier as a countermeasure against biological weapons. His efforts have been instrumental in expanding the definition of treatment countermeasure in Project BioShield legislation to include medical devices. Mr. Joyce recently served on the Project BioShield panel at the Federal Biodefense Research Conference, and was named Co-Chairman of the Bioterrorism/Chemical and Nuclear Security Task Force of the Homeland Security Industries Association. Mr. Joyce actively discusses issues related to infectious disease at various conferences, and has been featured in news stories on CNN, NBC, ABC, and other media outlets. From February 1993 until founding Aethlon Medical, Mr. Joyce was Chief Executive Officer of James Joyce & Associates. Previously, he was founder and Chief Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and played professional football for the Denver Broncos of the National Football League. Mr. Joyce is a graduate of the University of Maryland.
Rodney S. Kenley
President
Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and VP of Electronic Drug Infusion. During this tenure he conceived of and managed the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.
Mr. Kenley founded Aksys Ltd. in January 1991 to develop and commercialize his concept of a daily home hemodialysis system which was commercially launched in 2002 as the PHD system. In 2004, Mr. Kenley initiated the development of a second-generation home hemodialysis system in partnership with DEKA Research & Development Corporation in Manchester, New Hampshire. In 2007, the assets of Aksys Ltd. were acquired by DEKA, where Mr. Kenley was employed prior to joining Aethlon.
Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at the Kellogg School of Management at Northwestern University and at other business schools in the area of entrepreneurship.
Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg School of Management, also at Northwestern University.
James B. Frakes
Chief Financial Officer
Mr. Frakes joined Aethlon Medical in January 2008 and brought 16 consecutive years of financial responsibility for publicly traded companies, as well as, specific knowledge and experience in equity and debt transactions, acquisitions, public reporting and Sarbanes-Oxley section 404 internal control requirements. He previously served as the CFO for Left Behind Games Inc., a start-up video game company. Prior to 2006, he served as CFO of NTN Buzztime, Inc., an interactive entertainment company with $40 million in sales, where he played a key role in acquisitions that doubled the company's revenue.
Mr. Frakes received an MBA from the University of Southern California, and completed his BA with Honors at Stanford University.
Richard H. Tullis, Ph.D.
Senior Vice President, Chief Science Officer
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.
Contacts
James A. Joyce Chairman, CEO 858.459.7800 x301 jj@aethlonmedical.com
John P. Salvador Director, Communications & Investor Relations 858.459.7800 x307 jps@aethlonmedical.com
News for Aethlon Medical, Inc.:
Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) to Present at Biotech Showcase 2015 - January 8, 2015 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Approval of Ebola Treatment Protocol - January 2, 2015 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Initiates Patient Recruitment for FDA Approved Clinical Study - December 11, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients - December 2, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces $3.3 Million Equity Investment - November 28, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States - November 26, 2014 Medical Technology Breaking News: Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital - November 25, 2014 Medical Technology Breaking News: Time Magazine Names The Aethlon Hemopurifier® (OTCBB: AEMD) One of the 25 Best Inventions of 2014 - November 21, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Discloses Expanded Access "Emergency Use" Pathway To Treat Ebola in the United States - November 19, 2014 Medical Technology Breaking News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection - November 14, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) to Present at Tomorrow's SeeThruEquity Conference - November 11, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Presentation of Ebola Treatment Data This Friday, November 14th at the ASN Annual Meeting - November 10, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Undetectable Ebola Virus in Patient Treated with Hemopurifier® Therapy - November 6, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Discloses Ebola Treatment Pathways in the United States - October 29, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Treatment of an Ebola Patient - October 14, 2014 Medical Technology Breaking News: SeeThruEquity Issues Company Note on Aethlon Medical (OTCBB:AEMD) and Increase Target Price to $0.52 - October 7, 2014 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCBB: AEMD) – "A Pivotal Moment That Changed the NFL and CTE Research" - October 7, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players - September 26, 2014 Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Dengue Virus Treatment Agreement - September 25, 2014 Breaking Biodefense News: Aethlon Medical (NASDAQ:OTCQB: AEMD) Receives Notice of DARPA Contract Renewal - September 22, 2014 Medical Technology Breaking News: SeeThruEquity Initiates Research Coverage on Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD) with Target Price of $0.34 - September 22, 2014 Medical Technology Breaking News: Aethlon Medical (NASDAQ:OTCQB: AEMD) and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit - September 17, 2014 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL Players" - September 16, 2014 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) – "The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks" - September 10, 2014 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) Launches Digital Corporate Communication Channels - September 10, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform - September 8, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Receipt of IRB Approval to Initiate Hemopurifier™ Clinical Studies - September 2, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) CEO Note: A Novel Strategy To Address Ebola - August 6, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Online Access to Infectious Disease and Cancer Therapy Presentation - June 25, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at The Wall Street Analyst Forum - June 17, 2014 Medical Technology News: Medical Technology The Role of Aethlon Medical (OTCQB: AEMD) in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce - June 10, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients - May 21, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical Study - May 20, 2014 CEO Note: Cancer Treatment Discovery, Exosomes Transport Pharmaceutical Industry Targets - May 14, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) CEO Note: Cancer Therapy Publication References Aethlon Medical - April 22, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: U.S. Clinical Progression - April 9, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target - March 19, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce Brain Research Discoveries - March 5, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Agreement with DaVita Clinical Research - February 26, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Encouraging Meeting With CEO Jim Joyce - February 13, 2014 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at Biotech Showcase Investor Conference - January 7, 2014 Exosomes Sector Heats Up; Aethlon Medical (AEMD), Life Technologies (LIFE) and Eli (LLY) - January 3, 2014 Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics - December 17, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD): FDA Study, DARPA Milestones, Productive Operationally - November 20, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at SeeThruEquity Investor Conference - November 7, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: Grand Opening of Exosome Sciences Subsidiary on November 12th at 6:30pm Eastern - November 4, 2013 Aethlon Medical (OTCBB: AEMD) Gains 14.17% Following Note Authored by Chairman and CEO, Jim Joyce; Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor - October 25, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor - October 24, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: Clinical Partnering Programs, Manufacturing Optimization and Ramp-Up, Exosome Sciences Grand Opening - October 15, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Renewal of DARPA Dialysis-Like Therapeutics Contract - September 26, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc. - September 24, 2013 Medical Technology Q&A with Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc. - September 24, 2013 Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Closes up 12% on News of Launch of Exosome Science Subsidiary - September 13, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc. - September 13, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Launch of Exosome Sciences Subsidiary - September 12, 2013 Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at Exosomes and Circulating Biomarkers 2013 Summit - September 5, 2013 Medical Technology Research Alert: Zacks Small Cap Research Update for Aethlon Medical (OTCQB:AEMD); "Remain Encouraged By Ongoing Progress" - August 20, 2013 Technical Breakout; Aethlon Medical (OTCQB: AEMD) Sets Record Trading Highs - August 7, 2013 Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Trades at 52-Week High - August 6, 2013 Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Gains 21% - August 2, 2013 Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Announces European Patent to Remove Viruses From Blood - July 25, 2013 Battelle Team (NxStage Medical(NASDAQ: NXTM) and Aethlon Medical (OTCQB: AEMD) Wins DARPA Contract to Build Medical Device to Treat Sepsis - July 24, 2013 Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Gains 16% - July 22, 2013 Research Alert: Zacks Small Cap Research Increases Price Target for Aethlon Medical (OTCQB: AEMD) - July 19, 2013 Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Recent Progress Helps De-Risk Aethlon - July 18, 2013 Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors - July 12, 2013 Q&A with Chairman & CEO of Aethlon Medical (OTCQB: AEMD) Discussing FDA approval of IDE to Treat Hepatitis C (HCV) Patients and What's Next for the Aethlon Hemopurifier® - July 9, 2013 New Development for Treatment and Testing of Hepatitis C virus (HCV) - June 27, 2013 Trading Alert: Aethlon Medical, Inc. (OTCQB: AEMD) Spikes on FDA News - June 25, 2013 Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Reports FDA Approval of IDE to Treat Hepatitis C (HCV) Patients - June 25, 2013 Medical Technology Stock Alert: Aethlon Medical (OTCBB:AEMD) Note: An Update on the Clinical Status of the Aethlon Hemopurifier in Hepatitis-C Care - May 8, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013 - April 18, 2013 Biodefense Stock Alert; Aethlon Medical (OTCBB: AEMD) Moves Following News on Contract - April 17, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama - April 16, 2013 OTC Medical Device Stock Alert; Aethlon Medical (OTCBB: AEMD) Continues Gains, Up over 16% - March 15, 2013 Medical Device Stock Trading Alert: Aethlon Medical (OTCBB: AEMD) Gains over 10% in Early Trading - March 14, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer - February 28, 2013 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCBB:AEMD) Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com - February 11, 2013 Medical Technology Breaking News: Aethlon Medical, Inc. (OTCBB:AEMD) to Webcast, Live, at Retail InvestorConferences.com on February 7th - February 6, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: Since September 30th, 2011 / Thank You Shareholders - February 5, 2013 Medical Technology Breaking News: CORRECTION -- Aethlon Medical Inc (OTCBB:AEMD) - January 30, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses CEO Interview - January 29, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis - January 24, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) To Present Today At The 15th International Conference On Dialysis - January 23, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board - January 17, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: An Emerging Strategy to Treat Metastatic Breast Cancer - January 15, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) to Present Today At Biotech Showcase 2013 - January 8, 2013 Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses Submission of Hepatitis C Virus (HCV) IDE to FDA - January 3, 2013 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Expansion of Compassionate-Use Program To Treat Hepatitis C Virus (HCV) - December 12, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma - December 7, 2012 Medical Device Stock Trading Alert: Aethlon Medical (OTCBB: AEMD) Closes up 11.9% on News - December 4, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Initiation of Compassionate-Use Program to Treat Hepatitis C Virus (HCV) - December 3, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood - November 6, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Issuance of Cancer Therapy Patent - October 25, 2012 Biotech Stock News; RedChip Announces Live Video Webcast of 15th Annual Fall Small-Cap Conference - October 11, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) to Present at the RedChip 15th Annual Small-Cap Conference on October 11th - October 9, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Releases EXOSOMES & MICROVESICLES 2012 Presentation - October 3, 2012 Biotech Stock Breaking News; Aethlon Medical (OTCBB: AEMD) Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program - October 2, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board - September 26, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) To Present at the Exosomes and Microvesicles 2012 Conference - September 25, 2012 Biotech Stock News; RedChip Announces Presenting Companies for 15th Annual Fall Small-Cap Conference - September 18, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Discloses MD Anderson Cancer Center Presentation - September 11, 2012 Biotech Stock News; ThisweekinMedIT.tv features the Aethlon Medical Hemopurifier - September 10, 2012 Biotech Stock News; Wall Street Transcript Interview with Aethlon Medical, Inc. (OTCBB: AEMD) CEO James A. Joyce - August 30, 2012 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript - August 23, 2012 Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Reports Renewal of DARPA year-Two of Five-year $6.8 million Contract - August 22, 2012 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces Renewal of DARPA Dialysis-Like Therapeutics Contract - August 21, 2012 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces Expanded Access to Hemopurifier® Therapy For Individuals Infected with Hepatitis C Virus (HCV) - August 9, 2012 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports Undetectable Hepatitis C Virus (HCV) Seven Days After Initiation of Hemopurifier® Therapy in Genotype-1 Patients - July 31, 2012 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors - July 27, 2012 Biotech Stock Alert; Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available - June 27, 2012 Aethlon Medical (OTCBB:AEMD) Receives Patent Allowance Related to the Therapeutic Targeting of Exosomes that Promote Cancer Progression - June 20, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes - June 19, 2012 Medical Device Stock to Watch; Aethlon Medical (AEMD) Chairman and CEO Discusses Melanoma Exosomes - June 13, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis - June 12, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) to Present at Today's Security Research Associates 8th Annual Growth Conference - May 15, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy - May 8, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: Human Cytomegalovirus (HCMV) Validation - April 26, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: Marc Robins Joins the Aethlon Team - April 25, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier - April 24, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) to Present Hepatitis C (HCV) Treatment Technology at the 32nd Annual Dialysis Conference - February 7, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier Treatment Protocol - February 1, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Establishes Extracorporeal Therapy Scientific Advisory Board - January 23, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Establishes Sepsis & Inflammation Scientific Advisory Board - January 12, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Discloses Availability of the Biotech Showcase 2012 Presentation - January 10, 2012 OTC Biotech News; Aethlon Medical (OTC: AEMD) Announces Biotech Showcase 2012 Presentation - January 4, 2012 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Announces Biotech Showcase™ 2012 Presentation - January 4, 2012 OTC Biotech Stock News; Aethlon (OTCBB: AEMD) Reports HIV Breakthrough - December 14, 2011 Biotech Trading Alert: Aethlon Medical (OTCBB: AEMD) Trades Up over 9% on News of HIV-AIDS Research Discovery - December 13, 2011 Medical Stock Investor Alert; Aethlon Medical (OTCBB: AEMD) Announces HIV-AIDS Research Discovery - December 13, 2011 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes - December 6, 2011 Biotech Investor Alert for (OTC: AEMD), (Nasdaq:VRUS), (VRTX); Hepatitis C Virus (HCV) Treatments - November 28, 2011 Hepatitis C Virus (HCV) Biotech/ Pharma Stocks: (OTC: AEMD), (Nasdaq:VRUS), (VRTX) - November 25, 2011 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Releases Shareholder Letter - November 16, 2011 Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Trading Up over 19% - October 31, 2011 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) to Present at IN3 Medical Innovation Summit on October 27th - October 25, 2011 Tuesday's Biotech/ Pharma Stocks Trading: (OTC:AEMD),(AGEN), (HGSI), (LXRX) - October 19, 2011 Biotech Stock Alert; (OTC: AEMD) Trading Up 21% on News of Availability of its Exosome Detection Assay - October 18, 2011 Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Availability of its Exosome Detection Assay to the Research Community - October 18, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011 - October 5, 2011 Biotech Stock (OTC: AEMD) Doubles During Monday's Trading Following Report of $6.8 Million DARPA Contract - October 4, 2011 Biotech Stock Alert; (OTC: AEMD) Trading Up 50.88% on News of $6.8 million Contract from Defense Advanced Research Projects Agency (DARPA) - October 3, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Receives Government Contract Award from DARPA - October 3, 2011 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD), ImmunoGen (Nasdaq:IMGN) Report on HER2+ Breast Cancer Developments - September 29, 2011 Biotech/Medical Technology Stock News; "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc. (OTCBB: AEMD) - September 27, 2011 Biotech Stocks Reporting on Breast Cancer Treatments; (OTC: AEMD), (NASDAQ: SPPI), (NASDAQ:RXII), (OTCBB: GNBT) - September 23, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Introduces HER2osome, A Novel Therapeutic Device Strategy to Address Breast Cancer - September 21, 2011 Wednesday's Biotech Stocks Trading; LGND, CTIC, AVII, DNDN, OTC: AEMD - September 8, 2011 Biotech Stock Alert: Aethlon (OTCBB: AEMD) Makes Headlines with Cancer Studies - August 25, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies - August 24, 2011 Friday's Biotech/Pharma Stocks Trading; (OTCBB: AEMD), (BMY), (DNDN), (GSK) - August 15, 2011 Biotech/Pharma Stocks Trading: AEMD, ANX, OXGN, CHTP, EXEL - August 10, 2011 Biotech Stock Trading News; (OTCBB:AEMD), (NASDAQ:QCOR), (NASDAQ:MSHL), (NASDAQ:GILD) - July 28, 2011 Biotech/Pharma Stocks Investor Alert: AEMD, CAPS, ONTY, ANX, REGN - July 20, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter - July 15, 2011 Biotech/Pharma Stocks Investor Alert: AEMD, ZLCS, INO, VVUS, CYTR - July 6, 2011 Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy - June 28, 2011 Biotech/Pharma Stocks; (OTCBB: AEMD), (NYSE: BMY), (NasdaqGS: DNDN), (NYSE: GSK) Take A New Approach to Cancer - June 17, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 - June 8, 2011 Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks (OTCBB: AEMD), (NYSE: MRK) and (VRTX) - June 2, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) President Rodney S. Kenley to Present at the 20th International Vicenza Course on Hemodialysis and CKD - June 2, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) to Present the Aethlon ADAPT System at C21 BioVentures Life Sciences Partnering Conference - May 23, 2011 Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Introduces the Aethlon ADAPT System, Adaptive Dialysis-Like Affinity Platform - May 20, 2011 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Introduces the Aethlon ADAPT System - May 19, 2011 Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX) - May 17, 2011 Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV) - May 13, 2011 Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request for Hemopurifier® Investigational Device Exemption (IDE) - May 10, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV) - May 9, 2011 Biotech/ Biodefense Sector Trading Alert; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (NasdaqGM: SIGA) - May 5, 2011 Biotech/Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical (OTCBB: AEMD), ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL) - April 27, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Clarifies News Report - April 21, 2011 Biotech/Biodefense Stock News; ABC News Reports on Aethlon Medical (OTCBB: AEMD) - April 20, 2011 Biotech/Biodefense Stock News; RedChip Research Issues Research Update on Aethlon Medical (OTCBB: AEMD) - April 20, 2011 Biotech Stock Trading Alert; Aethlon Medical (OTCBB: AEMD) Trading up 12% in Morning Trading - April 18, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV - April 15, 2011 Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High - April 14, 2011 A Broad-Spectrum Treatment Strategy to Address HIV, Hepatitis-C (HCV) and other Infectious Disease Conditions; Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce - April 14, 2011 Biotech/ Biodefense Sector Trading Alert - April 8, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter - April 6, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Part II of Emerging Opportunities in Biodefense Interview - April 1, 2011 Emerging Opportunities in Biodefense Part II; An interview with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce - April 1, 2011 Biotech/Pharma Snapshot; Advances in Cancer Immunotherapy; (OTCBB: AEMD), (NYSE: BMY), Dendreon Corporation (NasdaqGS: DNDN) - March 29, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Emerging Opportunities in Biodefense Interview - March 25, 2011 Emerging Opportunities in Biodefense; An interview with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce - March 25, 2011 Biodefense Stocks Snapshot; (OTCBB: AEMD), (NasdaqCM: CBLI), (NYSE Amex: PIP), (NasdaqGM: SIGA) - March 22, 2011 Biotech Sector Snapshot HIV Drug Development; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE) - March 18, 2011 Biotech/Pharma Sector Close-Up; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE) - March 17, 2011 Biotech Stock News Alert; Aethlon Medical, Inc. (OTCBB:AEMD) Updates Shareholders - March 17, 2011 Biodefense Stocks; Aethlon Medical (OTCBB:AEMD) Discusses Device Opportunity To Treat Sepsis and Bioterror Threats - March 16, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Receives FDA Approval to Export its Hemopurifier® to India - March 8, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference - February 15, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) to Present at 4th Congress of the International Society for Hemodialysis in India - February 10, 2011 Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter - February 4, 2011
Media Link:
FDA allows testing of Aethlon device in Ebola patients - January 2, 2015
SeeThruEquity Issues Company Note on Aethlon Medical's First Treatment of Ebola Patient and Raises Target Price to $0.74 - November 18, 2014
These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections - November 12, 2014
Ebola Could Offer Significant Opportunity for AEMD - October 14, 2014
Aethlon Medical's OTC shares surge on use of device in Ebola treatment - October 14, 2014
Wocket quiere publicar tus fotos en competencia "Muéstranos tu billetera" - August 20, 2014
AEMD: Q1 Update, Revived Attention on Ebola - August 20, 2014
AEMD Further De-Risks Balance Sheet - July 16, 2014
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before - June 26, 2014
AEMD: Cancer Gaining More Traction As Target for Hemopurifier - May 29, 2014
Exosomes Common Link in Cancer Drug Development - May 15, 2014
Are Exosomes the Next PD-1 in Cancer Research? - April 30, 2014
Exosomes Shine a Light on Alzheimer’s Disease and CTE April 3, 2014
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases - March 13, 2014
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders - March 5, 2014
Aethlon Medical Expands Clinical Network Through DaVita Agreement - February 26, 2014
Invest in Exosomes Before Wall Street Does - wallstcheatsheet.com - December 31, 2013
AEMD: DARPA Picks Up Year-3 Option October 2, 2013
DARPA project aims to conquer blood disease August 23, 2013
AEMD: Remain Encouraged By Ongoing Progress August 19, 2013
Technical Stock Chart Analysis of Breakout Medical Device Company August 6, 2013
Aethlon Medical, Inc. (AEMD) Featured in Seeking Alpha article Plenty Of Room For Everyone In The Race To FDA Approval For New Hepatitis C Therapies July 23, 2013 includes: ABBV, BMY, ENTA, GILD, JNJ
Hemopurifier to be Studied as Treatment Option for Hepatitis C June 26, 2013 - Medgadget.com Hemopurifier Hemopurifier to be Studied as Treatment Option for Hepatitis C Aethlon Medical out of San Diego, CA has been investigating its Hemopurifier extracorporeal blood filtration device that has the potential to help manage a number of infectious diseases, as well as remove tumor-derived exosomes related to certain cancers.
FDA Approves Aethlon Medical Device for Clinical Testing June 26, 2013 - San Diego Business Journal The U.S. Food and Drug Administration has approved for clinical testing a blood purification device developed by San Diego-based biotech Aethlon Medical Inc.
FDA approves human feasibility study of device for treatment of HCV June 25, 2013 - Healio.com The FDA has approved an investigational device exemption for a human feasibility study of a medical device for treating patients with hepatitis C, according to a press release.
New IDE for Medical Device, Hepatitis C Investors to Ponder June 25, 2013 - AccessWire Aethlon Receives IDE Approval from FDA, Clears Way for Clinical Trials of New Hepatitis C Therapy
FDA Approves Human Study With Hemopurifier June 25, 2013 - By Zacks Small Cap Research
AEMD's Positive Recent Developments June 3, 2013
WellCare to join Georgia TeleHealth March 7, 2013
How Cancer Beats the Immune System March 7, 2013
Humana Reiterated Neutral March 6, 2013
REIT Companies Join to Webcast Live for Special March 7th RetailInvestorConferences.com Event March 5, 2013
Are Exosomes the Key to Stopping the Spread of Cancer? February 27, 2013
AEMD: DAPRA Revenue, Operational Progress Continues - February 14, 2013 By Zacks Equity Research
IDE Submitted Seeking Approval of U.S. Feasibility Study - January 3, 2013 By Zacks Equity Research
Aethlon's Non-Toxic Hepatitis C Approach Affirmed As Another Drug Trial Halted - August 20, 2012
AEMD Looking At Melanoma- June 13, 2012 By Zacks Small Cap Research
Our baby done growed up: Aethlon books first revenues ever on DARPA deal November 17, 2011 By MassDevice staffAethlon Medical books its first revenues ever, on a payment from its $6.8 million contract with the Defense Advanced Research Projects Agency to develop its Adapt blood filtration system for treating service members with combat injuries.
Aethlon Medical receives $6.8M DARPA contract, Sand Diego Source - October 3, 2011 By Daily Transcript staff report
Aethlon Medical Inc. (OTCBB: AEMD), a developer of therapeutic filtration devices, has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.
The contract program will utilize the Aethlon ADAPT system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis.
Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
The Aethlon award from DARPA is a fixed-price. five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.
Aethlon Medical, Inc. (OTCBB: AEMD) featured in Medical Design Online - September 21, 2011
San Diego Source - August 25, 2011 Aethlon Medical Inc.: Company announced it has entered into an agreement with the Sarcoma Oncology Center to study the effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
Aethlon Medical Ramping Up Activities in 2011; Redcip.com blog
Aethlon Medical Announces Multi-Target Exosome Assay Validation - April 15, 2011
Disclaimer: Corporate Profile as prepared and approved by featured company. * Investorideas.com disclaimer / disclosure
The following profile is a paid for submission/ad. Please read our full disclaimer and disclosure regarding specific compensation. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Become an Investor Ideas member today, login to stock directories and investor newsletter
News 
Market Data 
Discover 
